Power Law company profile

Sirna Therapeutics

Biotech & Life Sciences · San Francisco, United States · Founded 1992 · IPO 2006 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Investors

6 investors on Sirna Therapeutics's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series B+ 6 investors entered at this stage

Sprout Group

Notable Capital

Oxford Bioscience Partners

Venrock

Techno Venture Management

Granite Ventures

Patent intelligence

$63M patent portfolio · 27 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$63M

2.7× the top peer Aprogen ($23M)

27 active patent families

Where Sirna Therapeutics innovates Nucleic acid moleculeRNA interferenceRNAGene expressionDouble stranded rna

Above peer median on Market

Quality vs same-sector peers

Sirna Therapeutics on the five Patsnap quality dimensions

Sirna Therapeutics in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Sirna Therapeutics concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Sirna Therapeutics and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Sirna Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo